Manufacturing Stocks To Keep An Eye On – October 16th

Taiwan Semiconductor Manufacturing, Applied Materials, and Whitehawk Therapeutics are the three Manufacturing stocks to watch today, according to MarketBeat’s stock screener tool. Manufacturing stocks are shares of publicly traded companies whose main business is making physical goods through industrial processes—examples include automakers, machinery, electronics, chemical and consumer-goods manufacturers. Investors treat them as often cyclical, with earnings and stock prices tied to economic growth, capital spending, commodity costs and supply‑chain conditions, so they focus on metrics like production capacity, order backlogs, margins and free cash flow. These companies had the highest dollar trading volume of any Manufacturing stocks within the last several days.

Taiwan Semiconductor Manufacturing (TSM)

Taiwan Semiconductor Manufacturing Company Limited, together with its subsidiaries, manufactures, packages, tests, and sells integrated circuits and other semiconductor devices in Taiwan, China, Europe, the Middle East, Africa, Japan, the United States, and internationally. It provides a range of wafer fabrication processes, including processes to manufacture complementary metal- oxide-semiconductor (CMOS) logic, mixed-signal, radio frequency, embedded memory, bipolar CMOS mixed-signal, and others.

Applied Materials (AMAT)

Applied Materials, Inc. engages in the provision of manufacturing equipment, services, and software to the semiconductor, display, and related industries. The company operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells various manufacturing equipment that is used to fabricate semiconductor chips or integrated circuits.

Whitehawk Therapeutics (WHWK)

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.